NO20033446L - Medikament for behandling av osteonekrose og for behandling av pasienter som har riskio for a utvikle osteonekrose - Google Patents

Medikament for behandling av osteonekrose og for behandling av pasienter som har riskio for a utvikle osteonekrose

Info

Publication number
NO20033446L
NO20033446L NO20033446A NO20033446A NO20033446L NO 20033446 L NO20033446 L NO 20033446L NO 20033446 A NO20033446 A NO 20033446A NO 20033446 A NO20033446 A NO 20033446A NO 20033446 L NO20033446 L NO 20033446L
Authority
NO
Norway
Prior art keywords
osteonecrosis
treatment
medication
patients
risk
Prior art date
Application number
NO20033446A
Other languages
English (en)
Norwegian (no)
Other versions
NO20033446D0 (no
Inventor
David Graham Little
Nicholas Charles Smith
Original Assignee
Royal Alexandra Hosp Children
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from AUPR2907A external-priority patent/AUPR290701A0/en
Priority claimed from AUPR4187A external-priority patent/AUPR418701A0/en
Priority claimed from AUPR6654A external-priority patent/AUPR665401A0/en
Application filed by Royal Alexandra Hosp Children filed Critical Royal Alexandra Hosp Children
Publication of NO20033446D0 publication Critical patent/NO20033446D0/no
Publication of NO20033446L publication Critical patent/NO20033446L/no

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/66—Phosphorus compounds
    • A61K31/662—Phosphorus acids or esters thereof having P—C bonds, e.g. foscarnet, trichlorfon
    • A61K31/663—Compounds having two or more phosphorus acid groups or esters thereof, e.g. clodronic acid, pamidronic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
    • A61K31/197—Carboxylic acids, e.g. valproic acid having an amino group the amino and the carboxyl groups being attached to the same acyclic carbon chain, e.g. gamma-aminobutyric acid [GABA], beta-alanine, epsilon-aminocaproic acid or pantothenic acid
    • A61K31/198—Alpha-amino acids, e.g. alanine or edetic acid [EDTA]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/66—Phosphorus compounds
    • A61K31/675—Phosphorus compounds having nitrogen as a ring hetero atom, e.g. pyridoxal phosphate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A61K35/28—Bone marrow; Haematopoietic stem cells; Mesenchymal stem cells of any origin, e.g. adipose-derived stem cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/18—Growth factors; Growth regulators
    • A61K38/1825—Fibroblast growth factor [FGF]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/18—Growth factors; Growth regulators
    • A61K38/1841—Transforming growth factor [TGF]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/18—Growth factors; Growth regulators
    • A61K38/1875—Bone morphogenic factor; Osteogenins; Osteogenic factor; Bone-inducing factor
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22—Hormones
    • A61K38/30—Insulin-like growth factors, i.e. somatomedins, e.g. IGF-1, IGF-2
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/39—Connective tissue peptides, e.g. collagen, elastin, laminin, fibronectin, vitronectin, cold insoluble globulin [CIG]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
    • A61L27/00—Materials for grafts or prostheses or for coating grafts or prostheses
    • A61L27/50—Materials characterised by their function or physical properties, e.g. injectable or lubricating compositions, shape-memory materials, surface modified materials
    • A61L27/54—Biologically active materials, e.g. therapeutic substances
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P41/00—Drugs used in surgical methods, e.g. surgery adjuvants for preventing adhesion or for vitreum substitution
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
    • A61L2300/00—Biologically active materials used in bandages, wound dressings, absorbent pads or medical devices
    • A61L2300/20—Biologically active materials used in bandages, wound dressings, absorbent pads or medical devices containing or releasing organic materials
    • A61L2300/252—Polypeptides, proteins, e.g. glycoproteins, lipoproteins, cytokines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
    • A61L2300/00—Biologically active materials used in bandages, wound dressings, absorbent pads or medical devices
    • A61L2300/40—Biologically active materials used in bandages, wound dressings, absorbent pads or medical devices characterised by a specific therapeutic activity or mode of action
    • A61L2300/412—Tissue-regenerating or healing or proliferative agents
    • A61L2300/414—Growth factors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
    • A61L2430/00—Materials or treatment for tissue regeneration
    • A61L2430/02—Materials or treatment for tissue regeneration for reconstruction of bones; weight-bearing implants

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Zoology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Biomedical Technology (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Molecular Biology (AREA)
  • Developmental Biology & Embryology (AREA)
  • Cell Biology (AREA)
  • Rheumatology (AREA)
  • Hematology (AREA)
  • Dermatology (AREA)
  • Oral & Maxillofacial Surgery (AREA)
  • Transplantation (AREA)
  • Endocrinology (AREA)
  • Diabetes (AREA)
  • Biotechnology (AREA)
  • Virology (AREA)
  • Surgery (AREA)
  • Pain & Pain Management (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
NO20033446A 2001-02-06 2003-08-04 Medikament for behandling av osteonekrose og for behandling av pasienter som har riskio for a utvikle osteonekrose NO20033446L (no)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
AUPR2907A AUPR290701A0 (en) 2001-02-06 2001-02-06 A drug for the treatment of osteonecrosis and for the management of patients at risk of developing osteonecrosis
AUPR4187A AUPR418701A0 (en) 2001-04-03 2001-04-03 A drug for use in bone grafting
AUPR6654A AUPR665401A0 (en) 2001-07-27 2001-07-27 A drug and method for the treatment of osteonecrosis
PCT/AU2001/001616 WO2002062351A1 (en) 2001-02-06 2001-12-13 A drug for the treatment of osteonecrosis and for the management of patients at risk of developing osteonecrosis

Publications (2)

Publication Number Publication Date
NO20033446D0 NO20033446D0 (no) 2003-08-04
NO20033446L true NO20033446L (no) 2003-10-01

Family

ID=27158265

Family Applications (1)

Application Number Title Priority Date Filing Date
NO20033446A NO20033446L (no) 2001-02-06 2003-08-04 Medikament for behandling av osteonekrose og for behandling av pasienter som har riskio for a utvikle osteonekrose

Country Status (24)

Country Link
US (2) US7425549B2 (da)
EP (1) EP1365769B1 (da)
JP (1) JP2004527479A (da)
KR (1) KR20030072399A (da)
CN (1) CN1233325C (da)
AT (1) ATE496624T1 (da)
AU (1) AU2002221339B2 (da)
BR (1) BR0116862A (da)
CA (1) CA2435552C (da)
CY (1) CY1111402T1 (da)
CZ (1) CZ301361B6 (da)
DE (1) DE60143964D1 (da)
DK (1) DK1365769T3 (da)
HK (1) HK1061797A1 (da)
HU (1) HUP0303013A3 (da)
IL (1) IL157201A (da)
MX (1) MXPA03007029A (da)
NO (1) NO20033446L (da)
NZ (1) NZ527351A (da)
PL (1) PL361909A1 (da)
SI (1) SI1365769T1 (da)
SK (1) SK9862003A3 (da)
WO (1) WO2002062351A1 (da)
ZA (1) ZA200305890B (da)

Families Citing this family (27)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2435552C (en) * 2001-02-06 2010-04-27 The Royal Alexandra Hospital For Children A drug for the treatment of osteonecrosis and for the management of patients at risk of developing osteonecrosis
WO2002080933A1 (en) * 2001-04-03 2002-10-17 The Royal Alexandra Hospital For Children A drug for use in bone grafting
AU2002360619B2 (en) * 2001-12-21 2006-10-05 Allergan Pharmaceuticals International Limited Method for the treatment of bone disorders
CN100551377C (zh) 2002-05-10 2009-10-21 弗·哈夫曼-拉罗切有限公司 用于治疗和预防骨质疏松症的二膦酸
PL212072B1 (pl) * 2002-12-20 2012-08-31 Hoffmann La Roche Tabletka zawierająca jako substancję czynną do 250 mg kwasu ibandronowego oraz sposób jej wytwarzania
EP1534305B9 (en) 2003-05-07 2007-03-07 Osteologix A/S Treating cartilage / bone conditions with water-soluble strontium salts
JPWO2005072747A1 (ja) * 2004-02-02 2007-09-13 小野薬品工業株式会社 骨吸収抑制剤
ITMI20040218A1 (it) * 2004-02-10 2004-05-10 Abiogen Pharma Spa Uso di neridronato sodico per promuovere la neoformazione ossea
CA2557324C (en) 2004-02-26 2012-10-16 Osteologix A/S Strontium-containing compounds for use in the prevention or treatment of necrotic bone conditions
WO2008128056A1 (en) * 2004-10-08 2008-10-23 The Board Of Trustees Of The University Of Illinois Bisphosphonate compounds and methods with enhanced potency for multiple targets including fpps, ggpps, and dpps
EP1802641B8 (en) * 2004-10-08 2012-03-07 The Board Of Trustees Of The University Of Illinois Bisphosphonate compounds and methods for bone resorption diseases, cancer, bone pain, immune disorders, and infectious diseases
WO2006050493A2 (en) * 2004-11-03 2006-05-11 The Regents Of The University Of Michigan Biodegradable implant for intertransverse process fusion
US8071574B2 (en) * 2005-02-22 2011-12-06 John Dennis Bobyn Implant improving local bone formation
EP2001486A4 (en) * 2006-03-17 2010-12-29 Univ Illinois BIPHOSPHONATE COMPOUNDS AND CORRESPONDING METHODS
US7833270B2 (en) * 2006-05-05 2010-11-16 Warsaw Orthopedic, Inc Implant depots to deliver growth factors to treat osteoporotic bone
US8062364B1 (en) 2007-04-27 2011-11-22 Knee Creations, Llc Osteoarthritis treatment and device
US20160016982A1 (en) 2009-07-31 2016-01-21 Thar Pharmaceuticals, Inc. Crystallization method and bioavailability
US9169279B2 (en) 2009-07-31 2015-10-27 Thar Pharmaceuticals, Inc. Crystallization method and bioavailability
DK2459176T3 (da) 2009-07-31 2017-12-04 Gruenenthal Gmbh Krystallisationsfremgangsmåde og biotilgængelighed
WO2012071517A2 (en) 2010-11-24 2012-05-31 Thar Pharmaceuticals, Inc. Novel crystalline forms
GB201200868D0 (en) * 2012-01-19 2012-02-29 Depuy Int Ltd Bone filler composition
US10022172B2 (en) 2014-06-25 2018-07-17 Spine Wave, Inc. Minimally invasive posterolateral fusion
CN105012995B (zh) * 2015-06-04 2018-03-09 武汉维斯第医用科技股份有限公司 一种含促骨愈合药物的胶原蛋白海绵及其制备方法
US9775723B2 (en) 2015-06-16 2017-10-03 Spine Wave, Inc. Instrument and system for placing graft, implant and graft material for minimally invasive posterolateral fusion
EP3402803A4 (en) * 2016-01-14 2019-09-04 The Regents of The University of California METHOD OF TREATING ESTONEONE CRACKING WITH LLP2A-BISPHOSPHONATE COMPOUNDS
US10195218B2 (en) 2016-05-31 2019-02-05 Grunenthal Gmbh Crystallization method and bioavailability
AU2017204355B2 (en) 2016-07-08 2021-09-09 Mako Surgical Corp. Scaffold for alloprosthetic composite implant

Family Cites Families (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1994014455A1 (en) * 1992-12-23 1994-07-07 Merck & Co., Inc. Bisphosphonate/estrogen therapy for treating and preventing bone loss
US5403829A (en) * 1993-03-24 1995-04-04 Leiras Oy Use of bisphosphonates in endo-osteal bone surgery
US5646134A (en) * 1994-04-21 1997-07-08 Merck & Co., Inc. Alendronate therapy to prevent loosening of, or pain associated with, orthopedic implant devices
US5476865A (en) * 1994-07-06 1995-12-19 Eli Lilly And Company Methods of inhibiting bone loss
CN1113440A (zh) * 1994-07-29 1995-12-20 孟照强 一种治疗骨伤的中药制剂及其制备方法
WO1996039974A1 (en) * 1995-06-07 1996-12-19 Implex Corporation Femoral head core channel filling prosthesis
US7041641B2 (en) 1997-03-20 2006-05-09 Stryker Corporation Osteogenic devices and methods of use thereof for repair of endochondral bone and osteochondral defects
US5843678A (en) * 1997-04-16 1998-12-01 Amgen Inc. Osteoprotegerin binding proteins
US6316408B1 (en) * 1997-04-16 2001-11-13 Amgen Inc. Methods of use for osetoprotegerin binding protein receptors
AU750803B2 (en) * 1997-10-29 2002-07-25 University Of Pittsburgh Use of vectors such as adenoviruses and/or adeno associated viruses and/or retroviruses and/or herpes simplex viruses and/or liposomes and/or plasmids as a vehicle for genetic information enabling mammal cells to produce agents for the treatment of bone pathologies
US6268367B1 (en) * 1998-02-23 2001-07-31 Zymogenetics, Inc. Piperazine derivatives for treating bone deficit conditions
EP1121133A1 (en) 1998-10-15 2001-08-08 Merck & Co., Inc. Methods for stimulating bone formation
BR0010808A (pt) * 1999-05-21 2002-08-27 Novartis Ag Composições farmacêuticas e usos
AU781068B2 (en) * 1999-08-19 2005-05-05 Sydney Children's Hospitals Network (Randwick and Westmead) (incorporating The Royal Alexandra Hospital for Children), The Drug for treating fractures
AUPQ232599A0 (en) * 1999-08-19 1999-09-09 Royal Alexandra Hospital For Children, The Drug for treating fractures
AU6934600A (en) * 1999-08-27 2001-03-26 Board Of Regents, The University Of Texas System Cd40 ligand and cd40 agonist compositions and methods of use
GB0029111D0 (en) 2000-11-29 2001-01-10 Novartis Ag Organic compounds
CA2435552C (en) * 2001-02-06 2010-04-27 The Royal Alexandra Hospital For Children A drug for the treatment of osteonecrosis and for the management of patients at risk of developing osteonecrosis
AUPR553701A0 (en) 2001-06-07 2001-07-12 Royal Alexandra Hospital For Children, The A device for the delivery of a drug to a fractured bone

Also Published As

Publication number Publication date
NO20033446D0 (no) 2003-08-04
SI1365769T1 (sl) 2011-06-30
US20090005347A1 (en) 2009-01-01
NZ527351A (en) 2005-01-28
WO2002062351A1 (en) 2002-08-15
KR20030072399A (ko) 2003-09-13
ATE496624T1 (de) 2011-02-15
US7612050B2 (en) 2009-11-03
PL361909A1 (en) 2004-10-04
HK1061797A1 (en) 2004-10-08
IL157201A (en) 2010-04-29
DK1365769T3 (da) 2011-05-16
CY1111402T1 (el) 2015-08-05
US7425549B2 (en) 2008-09-16
ZA200305890B (en) 2005-01-26
CN1529604A (zh) 2004-09-15
BR0116862A (pt) 2004-01-13
JP2004527479A (ja) 2004-09-09
US20040097469A1 (en) 2004-05-20
AU2002221339B2 (en) 2006-04-27
HUP0303013A2 (hu) 2003-12-29
SK9862003A3 (en) 2004-02-03
MXPA03007029A (es) 2004-10-15
CA2435552A1 (en) 2002-08-15
HUP0303013A3 (en) 2007-06-28
CA2435552C (en) 2010-04-27
DE60143964D1 (de) 2011-03-10
EP1365769B1 (en) 2011-01-26
CZ301361B6 (cs) 2010-01-27
CZ20032408A3 (cs) 2004-06-16
EP1365769A1 (en) 2003-12-03
EP1365769A4 (en) 2005-08-10
CN1233325C (zh) 2005-12-28

Similar Documents

Publication Publication Date Title
NO20033446L (no) Medikament for behandling av osteonekrose og for behandling av pasienter som har riskio for a utvikle osteonekrose
NO20101190L (no) Anvendelse av buprenorfin i fremstillingen av et medikament
MXPA04011612A (es) Uso oftalmologico de roflumilasto para el tratamiento de enfermedades del ojo.
DE50008336D1 (de) Mehrschichttablette zur verabreichung einer fixen kombination von tramadol und diclofenac
BR0207883A (pt) Composições de medicamentos à base de anticolenérgicos e inibidores de pde-iv
SE0303571D0 (sv) Medical product for moisture-sensitive medicaments
BRPI0508865B8 (pt) dispositivo de liberação de medicamento visível por raio x
ATE353655T1 (de) Myo-inositol hexaphosphat zur topischen verwendung
PL408860A1 (pl) Telemedyczny sposób i system monitorowania pacjenta
BR0308154A (pt) Emprego de epotilonas no tratamento de doenças cerebrais associadas com processos proliferativos
PT998287E (pt) Utilizacao de levobupivacaina
NO994165L (no) Anvendelse av deskarboetoksyloratadin for fremstilling av et medikament for behandling av urininkontinens, reisesyke og svimmelhet
YU84503A (sh) Upotreba azitromicina za pripremanje leka za lečenje neinfektivnih inflamatornih oboljenja
BR0313413A (pt) Uso da vacinação beta amilóide juntamente com um inibidor da cox-2 seletivo para o tratamento da doença de alzheimer
DK1353948T3 (da) Oplöselige biologiske analoge til bata-amyloidpeptid
DE60222383D1 (de) Medikament zur verabreichung von amifostin und verwandten wirkstoffen
Stoddard et al. Pain management
NO20055137D0 (no) Kombinasjon av et makrolid og et lokalbedovelsesmiddel for behandling av hudsykdommer
AR025924A1 (es) Combinacion de loteprednol y agonistas de beta2-adrenoceptores
ATE487139T1 (de) Diagnostikum und therapeutikum gegen bauchspeicheldrüsenkrebs
MXPA03011186A (es) Uso de pentraxina ptx3 de cadena larga para tratamiento contra enfermedades tumorales mediadas por fgf-8.
MX2020007627A (es) Uso de la carrimicina o de sus ingredientes activos.
NO20042586L (no) Behandlingsfremgangsmate
BR0309684A (pt) O tratamento de dor com ifendropil
HUP0300876A2 (hu) Diklofenaksók alkalmazása égési sérülések helyi kezelésére használható gyógyszerkészítmény előállítására

Legal Events

Date Code Title Description
FC2A Withdrawal, rejection or dismissal of laid open patent application